Public filings / NRIX on Yahoo Finance (opens in a new tab)
NRIX: insider buying, 13F holders, analyst moves
Nurix Therapeutics, Inc.
A summary of public filings about Nurix Therapeutics, Inc. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
4 of our 100 managers hold NRIX
Combined reported value $580.9M.
Holders among our 100 managers: 2 in Q3 2023, 4 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| Deep Track Capital | $187.7M | 2.77% | Added |
| Rubric Capital | $175.3M | 1.61% | Added |
| Baker Bros. Advisors | $113.0M | 0.57% | Unchanged |
| Perceptive Advisors | $104.8M | 1.63% | Added |
SEC Form 4
Recent insider trades in NRIX
| Filed (ET) | Insider | Type | Value | Filing |
|---|---|---|---|---|
| 2026-10-15 17:00 | Hansen Gwenn Chief Scientific Officer | Sale | $36K | SEC |
As of the last site build. The live lookup shows 12 months of Form 4 filings.
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.